Clinical trial
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
NCT02267603 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT02267603 |
|---|---|
| Title | Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer |
| Official title | A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Merkel Cell Carcinoma, Stage III Merkel Cell Carcinoma AJCC v7, Stage IIIA Merkel Cell Carcinoma AJCC v7, Stage IIIB Merkel Cell Carcinoma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7 |
| Intervention type | Biological, Other |
| Interventions | Laboratory Biomarker Analysis, Pembrolizumab |
| Enrollment | 50 |
| Start date | Nov 25, 2014 |
| Primary completion | Feb 6, 2018 |
| Completion | Dec 15, 2021 |
| First posted | Oct 17, 2014 |
| Last update posted | Jul 5, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: